Stockscreener 앱 받기
149.69
1.11%
-1.68
시간 외 거래:
149.41
-0.28
-0.19%
전일 마감가:
$151.37
열려 있는:
$151.1
하루 거래량:
5.07M
Relative Volume:
0.78
시가총액:
$185.61B
수익:
$29.79B
순이익/손실:
$9.22B
주가수익비율:
20.37
EPS:
7.3494
순현금흐름:
$10.23B
1주 성능:
-0.80%
1개월 성능:
+2.01%
6개월 성능:
+8.38%
1년 성능:
+31.69%
1일 변동 폭
$149.59
$152.97
1주일 범위
$148.22
$154.20
52주 변동 폭
$108.46
$157.29
길리어드 사이언스 Stock (GILD) Company Profile
명칭
Gilead Sciences Inc
전화
(650) 574-3000
주소
333 LAKESIDE DR, FOSTER CITY, CA
Compare GILD vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
149.69 | 187.69B | 29.79B | 9.22B | 10.23B | 7.3494 |
LLY
Lilly Eli Co
|
1,181.89 | 1.03T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
270.68 | 648.67B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.12 | 468.43B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
147.98 | 365.34B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.57 | 271.25B | 54.66B | 13.58B | 16.05B | 7.0171 |
길리어드 사이언스 Stock (GILD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-10 | 개시 | Jefferies | Buy |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-02-11 | 재확인 | Needham | Buy |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-08-19 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | 업그레이드 | Truist | Hold → Buy |
| 2025-07-25 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 재확인 | Oppenheimer | Outperform |
| 2025-02-18 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-13 | 업그레이드 | DZ Bank | Hold → Buy |
| 2025-01-10 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 재개 | BofA Securities | Buy |
| 2024-11-15 | 개시 | Wolfe Research | Outperform |
| 2024-11-14 | 개시 | Citigroup | Buy |
| 2024-11-08 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2024-10-21 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-07 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 재확인 | Maxim Group | Buy |
| 2024-04-24 | 업그레이드 | HSBC Securities | Reduce → Hold |
| 2024-02-22 | 다운그레이드 | Truist | Buy → Hold |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-09-08 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-09-06 | 개시 | HSBC Securities | Reduce |
| 2023-07-24 | 재확인 | Barclays | Equal Weight |
| 2023-05-16 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 재개 | Piper Sandler | Overweight |
| 2023-01-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 재개 | BofA Securities | Neutral |
| 2022-12-09 | 다운그레이드 | DZ Bank | Buy → Hold |
| 2022-10-31 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 재확인 | BMO Capital Markets | Market Perform |
| 2022-10-28 | 재확인 | Cowen | Outperform |
| 2022-10-28 | 재확인 | JP Morgan | Overweight |
| 2022-10-28 | 재확인 | Jefferies | Buy |
| 2022-10-28 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-10-28 | 업그레이드 | Truist | Hold → Buy |
| 2022-10-28 | 재확인 | Wells Fargo | Equal Weight |
| 2022-10-04 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-28 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 재확인 | BMO Capital Markets | Outperform |
| 2022-02-02 | 재확인 | BofA Securities | Neutral |
| 2022-02-02 | 재확인 | RBC Capital Mkts | Outperform |
| 2022-02-02 | 재확인 | Truist | Hold |
| 2022-02-02 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Argus | Hold → Buy |
| 2022-01-06 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Neutral |
| 2021-11-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 재개 | Piper Sandler | Neutral |
| 2021-10-20 | 재개 | Cowen | Outperform |
| 2021-07-30 | 재확인 | BMO Capital Markets | Market Perform |
| 2021-07-30 | 재확인 | RBC Capital Mkts | Outperform |
| 2021-04-01 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | 업그레이드 | Redburn | Neutral → Buy |
| 2021-01-19 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-09-30 | 재개 | Jefferies | Buy |
| 2020-09-15 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-31 | 재확인 | Credit Suisse | Neutral |
| 2020-07-31 | 재확인 | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 재확인 | Piper Sandler | Overweight |
| 2020-07-31 | 재확인 | RBC Capital Mkts | Outperform |
| 2020-07-31 | 재확인 | SunTrust | Hold |
| 2020-07-31 | 재확인 | Wells Fargo | Equal Weight |
| 2020-07-20 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | 업그레이드 | SunTrust | Sell → Hold |
| 2020-05-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-05-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | 다운그레이드 | SunTrust | Hold → Sell |
| 2020-04-27 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-04-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | 다운그레이드 | CFRA | Hold → Sell |
모두보기
길리어드 사이언스 주식(GILD)의 최신 뉴스
Form DEF 14A Gilead Sciences Inc For: 24 September By Investing.com - Investing.com Canada
Gilead Sciences, Inc. (GILD) stock price, news, quote and history - Yahoo Finance Singapore
Gilead Sciences stock slips 0.85 percent ahead of the open - ad-hoc-news.de
Gilead: HIV Growth Is Not Enough At The Current Price (NASDAQ:GILD) - Seeking Alpha
Gilead Sciences stock slips 1.30 percent at the close - AD HOC NEWS
Gilead Sciences stock slips as earnings estimates shift - AD HOC NEWS
Can Gilead Sciences (NASDAQ:GILD) turn HIV leadership and oncology development into a stronger market story? - Kalkine Media
Gilead Sciences stock slips 0.7 percent ahead of the open - AD HOC NEWS
Gilead Sciences Research Scholars Program in Solid Tumors – US 2026 - Oncodaily
Better Healthcare ETF: Invesco's Biotech-Focused IBBQ vs. iShares' Broad IYH - The Motley Fool
Gilead Sciences (GILD) Stock Moves 1.40%: What You Should Know - finance.yahoo.com
Gilead Sciences stock slips 0.7 percent at the close - AD HOC NEWS
Gilead Sciences Inc. stock outperforms competitors on strong trading day - MarketWatch
Andra AP fonden Sells 11,400 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences FY2026 EPS Increased by Erste Group Bank - MarketBeat
THNR's Weight-Loss Index Swaps Hims & Hers for Gilead - ETF Database
Here's How Much $1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth Today - benzinga.com
Gilead Sciences stock holds near 52-week high as HIV prevention deal and analyst optimism support va - ad-hoc-news.de
Gilead Sciences, Inc. (GILD) Stock Analysis: Exploring Revenue Growth and Strategic Collaborations - directorstalkinterviews.com
Erste Group Bank Estimates Gilead Sciences FY2027 Earnings - MarketBeat
Gilead Sciences stock heads into the open after a 0.52% dip - ad-hoc-news.de
Gilead Sciences stock gains as HIV drug access expands - ad-hoc-news.de
Why Morgan Stanley likes Gilead’s HIV prevention play - thestreet.com
GILD: Gilead SciencesStock Price, Quote and News | NASDAQ - TechGraph
Why Is Gilead Sciences (GILD) Widening Lenacapavir Access Across 120 Countries? - finance.yahoo.com
Gilead Sciences (NASDAQ:GILD) Upgraded to Buy at Wall Street Zen - MarketBeat
Why Is Gilead Sciences (NASDAQ:GILD) in Focus Across S&P 500? - Kalkine Media
Nykredit A S Invests $140.59 Million in Gilead Sciences, Inc. $GILD - MarketBeat
[Press releases] Gilead Sciences provides updates on access to lenacapavir for HIV prevention - European AIDS Treatment Group
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know - finance.yahoo.com
Gilead Sciences (GILD) CFO Andrew Dickinson Sells 3,000 Shares a - GuruFocus
After $435,870 sale, Gilead (NASDAQ: GILD) CFO still holds 164K shares - Stock Titan
Gilead (NASDAQ: GILD) exec sells 3,000 shares in pre-arranged trades - Stock Titan
Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention - Business Wire
Another 3,000-share sale planned by Gilead (NASDAQ: GILD) executive - Stock Titan
Gilead Sciences Sees Yeztugo Powering HIV Growth as Oncology Pipeline Advances - finance.yahoo.com
Gilead, PAHO agree on HIV prevention drug access in Latin America, Caribbean - Reuters
Gilead Sciences Inc's Dividend Analysis - Yahoo Finance
Is Gilead Sciences (GILD) Reasonable Given Its Sales Base? - Yahoo Finance
Gilead Sciences, Inc. (GILD) Stock Analysis: Exploring a 10% Potential Upside with Strong Buy Ratings - directorstalkinterviews.com
Gilead Research Scholars Program in Solid Tumors 2026 - Oncodaily
Gilead Sciences, Inc. $GILD Stock Holdings Cut by Corient Private Wealth LP - MarketBeat
Sequoia Financial Advisors LLC Increases Position in Gilead Sciences, Inc. $GILD - MarketBeat
The Manufacturers Life Insurance Company Sells 148,344 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Bullseye Investment Management LLC Takes Position in Gilead Sciences, Inc. $GILD - MarketBeat
RSU vesting leaves Gilead (NASDAQ: GILD) CMO with 270 new shares after tax - Stock Titan
Gilead Sciences stock gains support as HSBC lifts price target to USD 175 - ad-hoc-news.de
Gilead Wins Appeals Court Ruling Blocking Imported HIV Drug Sales - Yahoo Finance
Gilead Advances $32B U.S. Investment With New California Research Center - Business Facilities
Why is Gilead Sciences (NASDAQ:GILD) stock in focus today? - Kalkine Media
Baird Financial Group Inc. Grows Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
길리어드 사이언스 (GILD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
0.01%
자본화:
|
볼륨(24시간):